New heart valve device shows early promise in small study

NCT ID NCT06510855

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study is testing a new device called the DurAVR™ THV System, which is a replacement heart valve placed through a small tube in the leg (TAVI procedure). The study includes 40 people with severe aortic stenosis or a failed surgical valve. The main goal is to see if the device is safe and feasible, looking at rates of death or disabling stroke at 30 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
DurAVR™ THV System (a replacement heart valve implanted via a catheter)
What this could lead to
If this device works well, it could offer a new, less invasive option for people with severe aortic stenosis who need a valve replacement.
What could go wrong
This is a very early, small study (40 people) focused on safety and feasibility. The device may not work as well as existing valves, and there are risks like bleeding, stroke, or death.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE CALCIFICATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Rigshospitalet

    Copenhagen, Capital Region of Denmark, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.